Arvinas (NASDAQ:ARVN) initiated with Buy rating and $35 (23% upside) price target at Roth Capital.
Bicycle Therapeutics (NASDAQ:BCYC) initiated with Buy rating and $17 (107% upside) at Roth.
Harpoon Therapeutics (NASDAQ:HARP) initiated with Buy rating and $25 (85% upside) price target at Roth.
Turning Point Therapeutics (NASDAQ:TPTX) initiated with Buy rating and $65 (33% upside) price target at Roth.
VBI Vaccines (NASDAQ:VBIV) initiated with Outperform rating and $3 (437% upside) price target at Raymond James. Shares up 10% premarket.
Vir Biotechnology (NASDAQ:VIR) initiated with Neutral rating and $17 (31% upside) price target at Baird.
QIAGEN (NYSE:QGEN) upgraded to Hold with a $36.31 (2% upside) price target at Kepler Cheuvreux. Upgraded to Overweight with a $40 price target at JPMorgan. Shares up 3% premarket.
ElectroCore (NASDAQ:ECOR) downgraded to Market Perform at JMP Securities. Shares down 13% after Q3 miss.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.